Ximelagatran (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ximelagatran" in English language version.

refsWebsite

Global rank English rank

11nih.gov

4^th place

8doi.org

2^nd place

3semanticscholar.org

11^th place

8^th place

2astrazenecaclinicaltrials.com

low place

1astrazeneca.com

low place

1web.archive.org

1^st place

astrazeneca.com

"AstraZeneca Decides to Withdraw Exanta" (Press release). AstraZeneca. February 14, 2006. Retrieved 2012-07-16.

astrazenecaclinicaltrials.com

"AZD0837". Astrazenecaclinicaltrials.com. Retrieved 2012-10-16.
"Long-term treatment with the oral direct thrombin inhibitor AZD0837, compared to Vitamin-K antagonists, as stroke prevention in patients with non-valvular atrial fibrillation and one or more risk factors for stroke and systemic embolic events. A 5-year follow-up study study". Clinical Study Report Synopsis. AstraZeneca. 21 January 2010. Trial D1250C0004221. Archived from the original on 10 November 2013.

doi.org

Hirsh J, O'Donnell M, Eikelboom JW (July 2007). "Beyond unfractionated heparin and warfarin: current and future advances". Circulation. 116 (5): 552–560. doi:10.1161/CIRCULATIONAHA.106.685974. PMID 17664384.
Ho SJ, Brighton TA (2006). "Ximelagatran: direct thrombin inhibitor". Vascular Health and Risk Management. 2 (1): 49–58. doi:10.2147/vhrm.2006.2.1.49. PMC 1993972. PMID 17319469.
Eriksson H, Wåhlander K, Gustafsson D, Welin LT, Frison L, Schulman S, et al. (THRIVE Investigators) (January 2003). "A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I". Journal of Thrombosis and Haemostasis. 1 (1): 41–47. doi:10.1046/j.1538-7836.2003.00034.x. PMID 12871538. S2CID 20556829.
Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al. (October 2003). "Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement". The New England Journal of Medicine. 349 (18): 1703–1712. doi:10.1056/NEJMoa035162. PMID 14585938. S2CID 26026547.
Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H (October 2003). "Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran". The New England Journal of Medicine. 349 (18): 1713–1721. doi:10.1056/NEJMoa030104. PMID 14585939.
Southworth H (July 2014). "Predicting potential liver toxicity from phase 2 data: a case study with ximelagatran". Statistics in Medicine. 33 (17): 2914–2923. doi:10.1002/sim.6142. PMID 24623062. S2CID 36324117.
Eikelboom JW, Weitz JI (April 2010). "New anticoagulants". Circulation. 121 (13): 1523–1532. doi:10.1161/CIRCULATIONAHA.109.853119. PMID 20368532.
Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, Wåhlander KF (December 2009). "Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists". European Heart Journal. 30 (23): 2897–2907. doi:10.1093/eurheartj/ehp318. PMC 2785945. PMID 19690349.

nih.gov

pubmed.ncbi.nlm.nih.gov

Hirsh J, O'Donnell M, Eikelboom JW (July 2007). "Beyond unfractionated heparin and warfarin: current and future advances". Circulation. 116 (5): 552–560. doi:10.1161/CIRCULATIONAHA.106.685974. PMID 17664384.
Ho SJ, Brighton TA (2006). "Ximelagatran: direct thrombin inhibitor". Vascular Health and Risk Management. 2 (1): 49–58. doi:10.2147/vhrm.2006.2.1.49. PMC 1993972. PMID 17319469.
Eriksson H, Wåhlander K, Gustafsson D, Welin LT, Frison L, Schulman S, et al. (THRIVE Investigators) (January 2003). "A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I". Journal of Thrombosis and Haemostasis. 1 (1): 41–47. doi:10.1046/j.1538-7836.2003.00034.x. PMID 12871538. S2CID 20556829.
Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al. (October 2003). "Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement". The New England Journal of Medicine. 349 (18): 1703–1712. doi:10.1056/NEJMoa035162. PMID 14585938. S2CID 26026547.
Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H (October 2003). "Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran". The New England Journal of Medicine. 349 (18): 1713–1721. doi:10.1056/NEJMoa030104. PMID 14585939.
Southworth H (July 2014). "Predicting potential liver toxicity from phase 2 data: a case study with ximelagatran". Statistics in Medicine. 33 (17): 2914–2923. doi:10.1002/sim.6142. PMID 24623062. S2CID 36324117.
Ahrens I, Peter K, Lip GY, Bode C (June 2012). "Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation". Discovery Medicine. 13 (73): 445–450. PMID 22742650.
Eikelboom JW, Weitz JI (April 2010). "New anticoagulants". Circulation. 121 (13): 1523–1532. doi:10.1161/CIRCULATIONAHA.109.853119. PMID 20368532.
Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, Wåhlander KF (December 2009). "Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists". European Heart Journal. 30 (23): 2897–2907. doi:10.1093/eurheartj/ehp318. PMC 2785945. PMID 19690349.

ncbi.nlm.nih.gov

Ho SJ, Brighton TA (2006). "Ximelagatran: direct thrombin inhibitor". Vascular Health and Risk Management. 2 (1): 49–58. doi:10.2147/vhrm.2006.2.1.49. PMC 1993972. PMID 17319469.
Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, Wåhlander KF (December 2009). "Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists". European Heart Journal. 30 (23): 2897–2907. doi:10.1093/eurheartj/ehp318. PMC 2785945. PMID 19690349.

semanticscholar.org

api.semanticscholar.org

Eriksson H, Wåhlander K, Gustafsson D, Welin LT, Frison L, Schulman S, et al. (THRIVE Investigators) (January 2003). "A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I". Journal of Thrombosis and Haemostasis. 1 (1): 41–47. doi:10.1046/j.1538-7836.2003.00034.x. PMID 12871538. S2CID 20556829.
Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al. (October 2003). "Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement". The New England Journal of Medicine. 349 (18): 1703–1712. doi:10.1056/NEJMoa035162. PMID 14585938. S2CID 26026547.
Southworth H (July 2014). "Predicting potential liver toxicity from phase 2 data: a case study with ximelagatran". Statistics in Medicine. 33 (17): 2914–2923. doi:10.1002/sim.6142. PMID 24623062. S2CID 36324117.

web.archive.org

"Long-term treatment with the oral direct thrombin inhibitor AZD0837, compared to Vitamin-K antagonists, as stroke prevention in patients with non-valvular atrial fibrillation and one or more risk factors for stroke and systemic embolic events. A 5-year follow-up study study". Clinical Study Report Synopsis. AstraZeneca. 21 January 2010. Trial D1250C0004221. Archived from the original on 10 November 2013.